CCN1 and neoplasm: CAR-T cell therapy represents a groundbreaking approach, where T cells are genetically engineered to express chimeric antigen receptors (CARs) that specifically recognize CYR61 on cancer cells, enabling them to attack and destroy CYR61-positive tumor cells [97].